Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Macromolecular Rapid Communications|February 20, 2025
Synergistic Molecular Engineering of Fully Non-fused Ring Acceptors for Achieving Efficient Zigzag Charge Transport Channel and Low Non-Radiative Voltage LossXiao-Peng Ru, Zhan Huang, Wen-Jing Sun, et al.
Science Translational Medicine|January 28, 2026
SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibitionYaogang Zhong, Feng Geng, Huali Su, et al.
Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.
Cancer Research|January 20, 2022
Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy EfficacyZhipeng Hong, Tao Liu, Lingfeng Wan, et al.
Cell Metabolism|May 28, 2013
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancerIvan Babic, Erik S Anderson, Kazuhiro Tanaka, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
Circulation Research|April 18, 2020
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19Peng Zhang, Lihua Zhu, Jingjing Cai, et al.
Pageof 10